
Scientists develop, validate scale to measure stigma in patients with sickle cell disease
New Delhi: Researchers in India have developed and validated a scale to measure stigma in a patient suffering from
sickle cell disease
and their caregivers.
Described in a paper in
The Lancet Regional Health Southeast Asia
journal, the '
ICMR-SCD Stigma Scale for India
' or ISSSI is the first such tool in the country and fourth in the world, available in clinical and research settings.
India accounts for the second-highest prevalence of sickle cell disease in the world, following sub-Saharan Africa.
The condition is a genetic disorder in which red blood cells are mis-shaped, affecting their ability to deliver oxygen.
The team, including researchers from the Indian Council for Medical Research (ICMR), said that despite the huge burden of sickle cell disease and associated stigma in India, not much research has been done, and no stigma measurement tool is available.
ISSSI characterises the nature of stigma under these categories -- perceived stigma, internalised stigma, experienced stigma and disclosure stigma.
The team's study developed and validated the ISSSI for patients and caregivers across six districts where sickle cell disease is endemic, including Alluri Seetharama Raju in Andhra Pradesh and Anuppur in Madhya Pradesh.
Findings highlight ISSSI's
psychometric robustness
and utility in clinical and research settings, the researchers said.
"The ISSSI (captures) multidimensional aspects of stigma, including familial and reproductive, social disclosure, illness burden, interpersonal, and healthcare interaction challenges," the authors wrote.
Future studies should apply the ISSSI scale across diverse cultural and linguistic contexts to improve its generalisability and impact, they said.
People with sickle cell disease often suffer from episodes of severe pain, chronic fatigue, swelling, infections, and potential organ damage, significantly impacting their quality of life.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
4 hours ago
- Time of India
COVID-19: Active cases cross 4,000 mark
New Delhi: India's active COVID-19 cases have crossed the 4,000 mark, with Kerala remaining the most affected state followed by Maharashtra, Gujarat, and Delhi, according to the Union Health Ministry data released on Tuesday. There are 4,026 active cases in India and five fresh deaths have been reported in the last 24 hours. Since January this year, 37 deaths have been reported in the country. There were 257 active patients in the country on May 22. The figure rose to 3,395 by May 31 and subsequently to 4,026 cases. Presently, Kerala has 1,446 active cases, the highest in the country followed by Maharashtra with 494, Gujarat with 397 and Delhi with 393 cases. Five deaths, one each in Kerala, Tamil Nadu and West Bengal and two deaths in Maharashtra, have been reported in the last 24 hours, according to the data. Official sources on May 31 stated that the COVID-19 situation in India is being closely monitored while stressing that the severity of infections is low, with most of the patients being under home care and that there was no cause for worry. Director General of Indian Council of Medical Research (ICMR) Dr Rajiv Behl on Monday stated that genome sequencing of samples in West and South have shown that the variants leading to the current rise in cases are not severe and are subvariants of Omicron only. The four variants that we have found are subvariants of Omicron,, LF.7, XFG, JN.1 and NB. 1.8.1. The first three have been found in more number of cases, he said. "We have been closely monitoring the situation. At this moment overall, we should monitor, be vigilant but there is no cause to worry," Dr Behl had said.


The Hindu
9 hours ago
- The Hindu
Work on BSL-3 virus research lab in Kozhikode progressing at a slow pace
The work on a biosafety level-3 (BSL-3) Virus Research and Diagnostic Laboratory is progressing at a slow pace at the Government Medical College Hospital, Kozhikode. The authorities are hopeful that it will be completed by the year-end. The proposal to upgrade the existing BSL-2 Virus Research and Diagnostic Laboratory under the State government to a regional-level lab was made after the Nipah outbreak in Kozhikode in 2018. As the regional lab should have BSL-3 standards, it was proposed to enhance the existing system there. According to sources, the Indian Council of Medical Research (ICMR) allocated ₹5.5 crore for the project in 2019. The estimate was later revised to ₹8 crore. The official process for the purpose was halted in the wake of the COVID-19 pandemic. The work began only in November 2021. Research on low-risk microbes is carried out at a BSL-1 lab and infectious organisms affecting humans can be dealt with at a BSL-2 lab. Indigenous or exotic microbes are handled at a BSL-3 lab, while deadly organisms require a BSL-4 lab. The sources said that the work is undertaken by the Central Public Works department. One of the reasons for the delay was a dispute between the contractor and the department, following which another contractor was assigned the work. It is learnt that the equipment for the lab is being purchased through Kerala Medical Services Corporation Ltd. A senior hospital official said on Tuesday (June 3) that the work could be completed by the end of this year, provided there were no further obstacles. At present, the body fluid samples of patients suspected to be suffering from highly infectious diseases such as Nipah are being sent to the National Institute of Virology, Pune, for confirmation tests. Once the lab is fully functional after getting the approval from the ICMR, such tests can be done here. Health Minister Veena George had said in the Assembly last year that the lab would become fully functional by 2027.


New Indian Express
10 hours ago
- New Indian Express
COVID-19: India's active cases cross 4,000 mark; five deaths in last 24 hours
NEW DELHI: India's active COVID-19 cases have crossed the 4,000 mark, with Kerala remaining the most affected state followed by Maharashtra, Gujarat, and Delhi, according to the Union Health Ministry data released on Tuesday. There are 4,026 active cases in India and five fresh deaths have been reported in the last 24 hours. Since January this year, 37 deaths have been reported in the country. There were 257 active patients in the country on May 22. The figure rose to 3,395 by May 31 and subsequently to 4,026 cases. Presently, Kerala has 1,446 active cases, the highest in the country followed by Maharashtra with 494, Gujarat with 397 and Delhi with 393 cases. Five deaths ---one each in Kerala, Tamil Nadu and West Bengal and two deaths in Maharashtra -- have been reported in the last 24 hours, according to the data. Official sources on May 31 stated that the COVID-19 situation in India is being closely monitored while stressing that the severity of infections is low, with most of the patients being under home care and that there was no cause for worry. Director General of Indian Council of Medical Research (ICMR) Dr Rajiv Behl on Monday stated that genome sequencing of samples in West and South have shown that the variants leading to the current rise in cases are not severe and are sub variants of Omicron only. The four variants that we have found are subvariants of Omicron --- LF.7, XFG, JN.1 and NB.1.8.1. The first three have been found in more number of cases, Dr Behl had said. "We have been closely monitoring the situation. At this moment overall, we should monitor, be vigilant but there is no cause to worry," he added.